MX2020002942A - Variantes de anticuerpos. - Google Patents

Variantes de anticuerpos.

Info

Publication number
MX2020002942A
MX2020002942A MX2020002942A MX2020002942A MX2020002942A MX 2020002942 A MX2020002942 A MX 2020002942A MX 2020002942 A MX2020002942 A MX 2020002942A MX 2020002942 A MX2020002942 A MX 2020002942A MX 2020002942 A MX2020002942 A MX 2020002942A
Authority
MX
Mexico
Prior art keywords
antibody variants
antibodies
tnfî
bind
binding
Prior art date
Application number
MX2020002942A
Other languages
English (en)
Inventor
Esther Maria Furrer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MX2020002942A publication Critical patent/MX2020002942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos que se unen a TNFa y exhiben una unión a FcRn modificada. Los anticuerpos de la invención tienen buenas funciones efectoras o propiedades farmacocinéticas.
MX2020002942A 2017-09-19 2018-09-11 Variantes de anticuerpos. MX2020002942A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17191988.9A EP3456737B1 (en) 2017-09-19 2017-09-19 Antibody variants
PCT/EP2018/074523 WO2019057565A1 (en) 2017-09-19 2018-09-11 ANTIBODY VARIANTS

Publications (1)

Publication Number Publication Date
MX2020002942A true MX2020002942A (es) 2020-07-22

Family

ID=59923274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002942A MX2020002942A (es) 2017-09-19 2018-09-11 Variantes de anticuerpos.

Country Status (15)

Country Link
US (1) US20200255511A1 (es)
EP (2) EP3456737B1 (es)
JP (2) JP7341127B2 (es)
KR (1) KR20200052307A (es)
CN (1) CN111108122A (es)
AR (1) AR113069A1 (es)
AU (1) AU2018335083A1 (es)
BR (1) BR112020005398A2 (es)
CA (1) CA3074249A1 (es)
EA (1) EA202090727A1 (es)
IL (1) IL272951A (es)
MX (1) MX2020002942A (es)
SG (1) SG11202001465WA (es)
TW (1) TWI818923B (es)
WO (1) WO2019057565A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
EP2943506B1 (en) 2013-01-10 2024-03-13 Genmab B.V. Human igg1 fc region variants and uses thereof
ES2836349T3 (es) * 2016-03-17 2021-06-24 Tillotts Pharma Ag Anticuerpos anti-TNF-alfa y fragmentos funcionales de los mismos

Also Published As

Publication number Publication date
AR113069A1 (es) 2020-01-22
EP3684808A1 (en) 2020-07-29
WO2019057565A1 (en) 2019-03-28
TW201915019A (zh) 2019-04-16
CA3074249A1 (en) 2019-03-28
US20200255511A1 (en) 2020-08-13
CN111108122A (zh) 2020-05-05
EA202090727A1 (ru) 2020-06-15
EP3456737A1 (en) 2019-03-20
KR20200052307A (ko) 2020-05-14
AU2018335083A1 (en) 2020-04-02
IL272951A (en) 2020-04-30
BR112020005398A2 (pt) 2020-09-29
SG11202001465WA (en) 2020-04-29
JP2020534000A (ja) 2020-11-26
JP7341127B2 (ja) 2023-09-08
JP2023109960A (ja) 2023-08-08
EP3456737B1 (en) 2024-02-14
TWI818923B (zh) 2023-10-21

Similar Documents

Publication Publication Date Title
PH12019502282A1 (en) Bispecific antibodies specifically binding to pd1 and lag3
MX2022005211A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
WO2017091656A8 (en) Heterodimeric antibodies that bind cd3 and cd38
PH12018502054A1 (en) Antibodies recognizing tau
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2019013045A (es) Anticuerpos que reconocen tau.
MY197413A (en) Antibodies recognizing tau
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
MX2022015258A (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
CR20200313A (es) VARIANTES DE DOMINIO DE Fc DE IgG HUMANA CON FUNCIÓN EFECTIVA MEJORADA
MX2018002467A (es) Anticuerpos y ensayos para deteccion del antigeno leucocitico (cd37).
PH12020500473A1 (en) Antibody variants
MX2020002934A (es) Variantes de anticuerpos.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
WO2015117057A3 (en) Protein m related immunoglobulin-binding polypeptides
MX2020002942A (es) Variantes de anticuerpos.
WO2014201400A3 (en) Anti-factor viii antibodies or uses thereof
CR20210332A (es) Anticuerpo que se une a vegf y a il-1beta y métodos de utilización
EP3565845A4 (en) ERBB2 ANTIBODIES AND THEIR USES
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
WO2016140860A3 (en) Peptide linker for attachment of thiol-reactive molecules to surfaces